GlassScriptPhysician profile
Mark A Meadors
NPI 1962593731
$8,238.32
in general payments reported to CMS, 2019-2025
55 companies · $1,181 in 2025
The $1,181 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,492 · 2020: $548 · 2021: $1,191 · 2022: $1,053 · 2023: $1,637 · 2024: $1,137 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,464 · Education: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,464.01 |
| Education | $490.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,038.81 | 2019-2024 | |
| Janssen Biotech, INC. | $710.48 | 2019-2025 | Rybrevant, Erleada, Akeega |
| Astrazeneca Pharmaceuticals LP | $467.10 | 2019-2025 | Enhertu, Calquence, Lynparza |
| Merck Sharp & Dohme LLC | $459.86 | 2019-2024 | Keytruda, Welireg |
| Seagen INC. | $459.65 | 2020-2023 | Padcev, Tukysa |
| Emd Serono, INC. | $433.48 | 2019-2025 | Bavencio |
| Lilly USA, LLC | $424.14 | 2019-2024 | Retevmo, Jaypirca |
| Gilead Sciences, INC. | $409.32 | 2021-2025 | Trodelvy |
| Incyte Corporation | $316.88 | 2019-2024 | Monjuvi, Jakafi, Pemazyre |
| Amgen INC. | $305.77 | 2019-2025 | Imdelltra (Amg757), Lumakras, Kyprolis |
| Celgene Corporation | $304.53 | 2019-2025 | Reblozyl |
| Daiichi Sankyo INC. | $300.45 | 2019-2025 | Injectafer, Datroway |
| Pfizer INC. | $187.08 | 2019-2025 | |
| Eisai INC. | $172.64 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.45 | 2019-2023 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $132.11 | 2023-2025 | Fruzaqla, Iclusig |
| E.R. Squibb & Sons, L.L.C. | $131.05 | 2019-2024 | Opdivo |
| Exelixis INC. | $128.14 | 2019-2023 | Cabometyx |
| Myriad Genetic Laboratories, INC. | $123.22 | 2022-2025 | Myrisk, Endopredict |
| Glaxosmithkline, LLC. | $117.90 | 2021-2025 | Ojjaara, Shingrix |
| Stemline Therapeutics INC. | $109.16 | 2023-2025 | Orserdu |
| Dendreon Pharmaceuticals LLC | $99.66 | 2023-2025 | Provenge |
| Genzyme Corporation | $96.17 | 2019-2022 | |
| Adaptive Biotechnologies Corporation | $74.96 | 2021-2024 | Clonoseq |
| Foundation Medicine, INC. | $67.54 | 2023 | |
| Abbvie INC. | $55.62 | 2019-2021 | |
| Astellas Pharma US INC | $53.71 | 2021-2023 | Padcev |
| Beone Medicines USA, INC. | $53.09 | 2025 | Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $52.52 | 2019-2023 | Imbruvica |
| Heron Therapeutics, INC. | $51.71 | 2021 | |
| Genentech USA, INC. | $50.86 | 2019-2023 | Tecentriq |
| Aveo Pharmaceuticals, INC. | $50.74 | 2021-2023 | Fotivda |
| Karyopharm Therapeutics INC. | $50.62 | 2022-2023 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.63 | 2019-2023 | Gilotrif |
| Tempus Ai, INC | $46.17 | 2024-2025 | Xt Cdx |
| Kite Pharma, INC. | $44.97 | 2021-2023 | Yescarta |
| Regeneron Healthcare Solutions, INC. | $42.42 | 2024 | Libtayo |
| Beigene USA, INC. | $40.61 | 2023-2025 | Tevimbra, Brukinsa |
| Jazz Pharmaceuticals INC. | $32.69 | 2023-2025 | Zepzelca |
| Rigel Pharmaceuticals, INC. | $31.76 | 2023-2024 | Rezlidhia, Tavalisse |
| Medtronic, INC. | $31.59 | 2025 | Synchromedii |
| Pharmacosmos Therapeutics INC. | $30.34 | 2025 | Monoferric |
| Clovis Oncology, INC. | $29.41 | 2019 | |
| Array Biopharma INC | $28.61 | 2021-2023 | Braftovi, Xalkori, Lorbrena |
| Tersera Therapeutics LLC | $24.13 | 2019 | |
| Mirati Therapeutics, INC. | $24.03 | 2024 | Krazati |
| Adc Therapeutics America, INC. | $22.65 | 2025 | |
| Progenics Pharmaceuticals, INC. | $22.43 | 2022 | |
| Taiho Oncology, INC. | $20.63 | 2023 | |
| Blueprint Medicines Corporation | $15.98 | 2023 | Ayvakit |
| G1 Therapeutics, INC. | $15.63 | 2023 | Cosela |
| Epizyme, INC. | $14.36 | 2022 | |
| Servier Pharmaceuticals LLC | $12.89 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.92 | 2019 | |
| Verastem, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Meadors listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.